Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-azacitidine in HPV+ vs HPV- HNSCC
NCT02178072Phase 1Completed
- Sponsor
- Yale University
- Start
- Feb 2015
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of azacitidine in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Yale University. Primary endpoints: Tumor response at 6 months and Proportion of HPV-positive patients with increased APOBEC RNA expression. Started Feb 2015; status: completed.
02
Drugs
azacitidine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02178072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02178072.